Anvar Babaev is a Cardiology physician affiliated with New York University. OpenAlex indexes 7 publications with 680 citations (h-index 3); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
550 1st Ave
Th576
New York, NY 100166402
Telephone
212-263-5656Provider last certified this registry record 22 Aug 2024.
Clinical trials
- Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal
Sponsor: Abbott Medical Devices
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202522 payments$10,793openpaymentsdata.cms.gov ↗
- Shockwave Medical, IncProgram year202512 payments$10,722openpaymentsdata.cms.gov ↗
- Medtronic, Inc.Program year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.8%Statin13.8%Rosuvastatin Calcium49%Atorvastatin Calcium47%Crestor3%Pravastatin Sodium2%Part D<11 patientsBeta blocker13.2%Metoprolol Succinate78%Carvedilol15%Metoprolol Tartrate7%Part D≥101 patients+ 15 more classes in this area
Blood & clotting
25.2%P2Y12 inhibitor17.5%Clopidogrel89%Brilinta5%Prasugrel Hcl4%Effient2%Part D<11 patientsFactor Xa inhibitor7.1%Eliquis65%Xarelto35%Part D≥34 patients+ 1 more class in this area
Metabolism & gastrointestinal
2%Proton pump inhibitor0.8%Pantoprazole Sodium100%Part D<11 patientsPotassium supplement0.8%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- B-44 | Ischemic electrocardiographic changes are uncommon in patients with myocardial injury following elective percutaneous coronary intervention
Journal of the Society for Cardiovascular Angiography & Interventions
2026 - Incidence and prognostic value of electrocardiographic changes in patients with myocardial injury after elective PCI
Cardiovascular revascularization medicine
2026 - TCT-692 First Clinical Use of a Novel Forward-Shifted Peripheral Intravascular Lithotripsy System: Primary Outcomes of the Mini S/FORWARD PAD IDE Study
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Galetta, MD
New York University
Herbert Lepor, MD
New York University
Aasma Shaukat, MD
New York University
Jerry Shapiro, MD
New York University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”